Zoetis Inc. (NYSE:ZTS) Shares Purchased by ICW Investment Advisors LLC

ICW Investment Advisors LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 22.6% in the 4th quarter, Holdings Channel reports. The firm owned 4,989 shares of the company’s stock after purchasing an additional 920 shares during the period. ICW Investment Advisors LLC’s holdings in Zoetis were worth $813,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares during the last quarter. Dunhill Financial LLC raised its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Asset Planning Inc acquired a new position in shares of Zoetis during the 4th quarter worth about $58,000. Finally, Quarry LP raised its position in shares of Zoetis by 45.9% during the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after purchasing an additional 96 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ZTS shares. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Piper Sandler upped their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $215.90.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,862 shares of company stock valued at $312,254. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $162.86 on Monday. The firm has a 50 day simple moving average of $166.76 and a 200-day simple moving average of $175.38. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock has a market cap of $72.93 billion, a price-to-earnings ratio of 29.77, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. Zoetis’s payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.